Linda Jaber

Wayne State University, Detroit, MI B.S. 1983 Pharmacy

Wayne State University, Detroit, MI Pharm.D. 1986 Pharmacy

A. POSITIONS
 
1983 - 1984  Staff Pharmacist; Apex Drugs, Detroit, MI.
1986 - 1987  Research Associate; College of Pharmacy, Wayne State University, Detroit, MI.
1987 - 1989  Clinical Lecturer; College of Pharmacy, Wayne State University, Detroit, MI.
1989 - 1996  Assistant Professor; College of Pharmacy, Wayne State University, Detroit, MI.
1996 - present  Associate Professor; College of Pharmacy, Wayne State University, Detroit, MI

B. Research Support

Principal Investigator.  “The epidemiology of diabetes and its risk factors among Arab Americans”.
The American Diabetes Association Clinical Research Award.
Grand Award total: $299,745; # years: 3
1st year: $99,792/January 2000
2nd year: $99,992/January 2001
3rd year: $99,961/January 2002

Co-Principal Investigator.  “The epidemiology of diabetes and its risk factors among Arab/Chaldean population”
Blue Cross Blue Shield of Michigan Foundation
Grand Award total: $146,535; # years: 2
1st year: $70,186/May 2001

1982 Rho Chi Pharmaceutical Honor Society
1985-1986 Wayne State University Graduate/Professional Scholarship
1989-1990 Instructor of the year
1993 Nominated for the Probus Club Award for Academic Achievement
1993-1994 Teacher of the Year
1994 MSHP Research Award

Demers R.Y., Neale A.V., Wenzloff N.J., Gronsman K.J., Jaber L.A. \"Glycosylated hemoglobin levels and self-reported stress in adults with diabetes\". Behavioral Medicine 1989;15:167-172.

Jaber L.A., Wenzloff N.J., Komanicky P., Antal E.J. \"An evaluation of the therapeutic effects and dosage equivalence of glyburide and glipizide\". J. Clin Pharmacol 1990:30:181-188.

Jaber L.A., Melchior W., Ruthledge D. \"Possible correlation between glycemia and blood pressure in black, diabetic, hypertensive patients\". The Annals of Pharmacothera 1992;26:882-886.

Jaber L.A. \"The pharmacology of reformulated glyburide\". Patient Care Clinical Focus/September 1992;29-34.

Jaber L.A., Lewis N.J.W., Slaughter R.L., Neale A.V. \"The effect of stress on glycemic control in patients with type II diabetes during glyburide and glipizide therapy\". J Clin Pharmacol 1993;33:239-245.

Jaber L.A., Antal E.J., Slaughter R.L., Welshman I.R. \"The Pharmacokinetics and Pharmacodynamics of 12 week glyburide therapy in obese diabetics.\" Eur J Clin Pharmacol 1993;45:459-463.

Jaber L.A., Antal E.J., Slaughter R.L., Welshman I.R. \"Comparison of pharmacokinetics and pharmacodynamics of short- and long-term glyburide therapy in NIDDM.\" Diabetes care 1994;17:1300-1306.

Jaber, L.A., Slaughter R.L., Grunberger G. \"Diabetes and related metabolic risk factors among Arab Americans\". Ann Pharmacother 1995;29:573-575.

Jaber L.A., Ducharme M.Pc., Edwards D.J., Slaughter R.L, Grunberger G. \"The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with NIDDM\". Pharmacother 1996;16:760-768.

Jaber, L.A., Antal E.J., Welshman I.R. \"Pharmacokinetics and pharmacodynamics of glyburide in young and elderly patients with NIDDM\". Ann Pharmacother 1996;30:472-475.

Jaber, L.A., Ducharme M.Pc., Halapy Ha. \"The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with NIDDM\". Therapeutic Drug Monitoring 1996;18:6-13.

Jaber L.A., Halapy Ha., Fernet Ma., Tummalapalli Sb., Diwakaran Hb. \"Evaluation of a pharmaceutical care model on diabetes management\". Ann Pharmacother 1996;30:238-243.

Sonnenberg GE, Garg DC, Weidler DJ, Dixon RM, Jaber LA, Bowen AJ, et.al. “Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus”. Ann Pharmacother 1997;31:671-676.

Halapy H., Jaber L.A. “Diabetes management: follow-up”. Ann Pharmacother 1997;31:371 (Letter)

Jaber LA, Nowak SNa, Slaughter RR. “Efficacy of insulin-metformin combination therapy in obese patients with type 2 diabetes”. J Clin Pharmacol 2002;42:89-94

Nowak SNa, Edwards DJ, Clarke A, Anderson GD, Jaber LA. Pioglitazone: effect on CYP3A4 activity. J Clin Pharmacol 2002;42(12):1299-1302

Jaber LA. “Glyburide/glipizide combination therapy in type 2 diabetes”. J Pharm Technol 2002;18:9-12

Nowak SNa, Singh R, Clarke A, Campbell E, Jaber LA. “Metabolic control and adherence to American Diabetes Association practice guidelines in a pharmacist-managed diabetes clinic” Diabetes Care 2002;25:1479 (letter)

Jaber LA, Brown MB, Hammad A, Nowak SN, Zhu Q, Ghafoor A, Herman WH. Epidemiology of diabetes among Arab Americans. Diabetes Care 2003;26:308-313.

Jaber LA. Barriers and strategies for research in Arab Americans. Diabetes Care 2003;26: 514-5 (commentary)

Jaber LA, Brown MB, Hammad A, Zhu Q, Herman WH. “The prevalence of the metabolic syndrome among Arab Americans”. Diabetes Care 2004;27:234-238.

Jaber LA, Brown MB, Hammad A, Zhu Q, Herman WH. “Lack of acculturation is a risk factor for diabetes in Arab immigrants in the U.S”. Diabetes Care 2003;26:2010-2014.